Clin2
NCT07114419Possibly a fitRecruiting

New weekly injection for weight loss in overweight or obesity

Obesity and Overweight

Treatments studied

Part of Hormones & metabolism clinical trials.

This study tests a new weekly injection, efsubaglutide alfa (a GLP-1 drug), for helping people with overweight or obesity lose weight. It is for people who have not been able to lose weight with diet and exercise alone and do not have other serious health conditions.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
200 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • You are obese (BMI 30 or higher) or overweight (BMI 27-30) with at least one weight-related health condition.
  • You have not had diabetes (type 1 or type 2).
  • You have not taken weight-loss medications or certain other medicines in the past 3 months.
  • You have not had weight-loss surgery or liposuction in the past year.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07693426Recruiting· Phase 1
Study of efsubaglutide alfa for obese teenagers

This trial tests an injection called efsubaglutide alfa to help obese teenagers lose weight. It requires following diet and exercise advice for at least 3 months before starting.

Beijing, Beijing Municipality
NCT06633783Not yet recruiting· Phase 3
Weekly shot for weight loss in adults with obesity

This study tests a weekly injection called semaglutide to see how well it helps people with obesity lose weight, compared to a similar approved medicine, Wegovy. It may be an option if you have struggled to lose weight in the past.

Xuancheng, Anhui
NCT06900075Not yet recruiting· Phase 3
Study of an every-other-week injection for type 2 diabetes

This study tests an investigational shot (given every two weeks) that may help lower blood sugar in people with type 2 diabetes. Participation involves regular check-ups and blood tests to see how well the treatment works for you.

NCT07518121Not yet recruiting· Phase 1
New medicine test in healthy adults

This study tests a new medicine called Efsubaglutide Alfa in healthy adults. It is a first-in-human study to see how the drug is absorbed, broken down, and eliminated by the body. This study is for healthy volunteers only, not patients.

Valinhos, São Paulo
NCT07400107Not yet recruiting· Phase 3
New weekly injection for weight loss in type 2 diabetes

This study tests a new weekly injection (called NNC0487-0111) against an existing medicine (semaglutide) to see if it helps people with type 2 diabetes lose more weight. Together with standard diabetes care and lifestyle changes, you would receive the study medicine for about a year, and the study team will monitor your health and weight.

Hollywood, Florida
NCT07622810Not yet recruiting· Phase 3
Weight loss injection compared to a standard treatment

This study tests a new injection called bofanglutide to see if it helps people with overweight or obesity lose more weight than a standard treatment. It is for adults who have not been able to lose weight with diet and exercise alone.

Guadalajara, Jalisco

Hear when a new Obesity and Overweight trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.